Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Rhea-AI Summary

Innoviva reported third quarter 2024 financial results, highlighting strong performance and significant progress. Key points include:

Royalty revenue: $60.5 million from GSK, a 6% year-over-year increase.

Net product sales: $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% growth. GIAPREZA® contributed $13.1 million, XERAVA® $2.3 million, and XACDURO® $4.3 million.

License revenue: $4.6 million from development cost-sharing reimbursements.

Net income: $1.2 million, or $0.02 per share, down from $82.0 million, or $1.26 per share in Q3 2023.

Cash and assets: $260.6 million in cash and equivalents, with $91.1 million in receivables.

Notable achievements include the nomination of XACDURO® for the 2024 Prix Galien USA Award and plans to submit an NDA for zoliflodacin in early 2025.

Positive

• 6% year-over-year growth in royalty revenue from GSK, totaling $60.5 million.
• 68% year-over-year growth in U.S. net product sales, reaching $19.7 million.
• Nomination of XACDURO® for the 2024 Prix Galien USA Award.
• Plans to submit an NDA for zoliflodacin in early 2025.

Negative

• Net income decreased significantly to $1.2 million from $82.0 million in Q3 2023.
• Unfavorable net change in fair value of equity and long-term investments by $35.2 million, primarily due to lower share price of Armata Pharmaceuticals.

Insights

Financial Analyst

The Q3 2024 results show mixed performance. Core royalty revenue from GSK grew 6% year-over-year to $60.5 million, while IST's U.S. product sales jumped 68% to $19.7 million. However, net income declined significantly to $1.2 million ($0.02 per share) from $82.0 million ($1.26 per share) in Q3 2023, primarily due to a $35.2 million loss from equity investments.

The company maintains a strong balance sheet with $260.6 million in cash and $91.1 million in receivables. The commercial portfolio shows promising growth, particularly GIAPREZA® with $13.1 million in sales. The upcoming zoliflodacin NDA submission in early 2025 represents a significant growth catalyst.

Medical Research Analyst

The pipeline developments and clinical data presentations demonstrate solid progress in Innoviva's infectious disease portfolio. XACDURO®'s Prix Galien USA Award nomination validates its innovative approach to treating resistant Acinetobacter infections. The zoliflodacin program shows particular promise, with multiple positive data presentations supporting its potential as a first-in-class treatment for gonorrhea. The successful Phase 3 results and planned FDA submission position it as a significant near-term value driver.

Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth

Innoviva Specialty Therapeutics’ (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements.

“For the third quarter of 2024, we continue to deliver strong revenue growth, with solid performance from our core GSK royalty assets, and accelerating sales from our IST commercial products, GIAPREZA^®, XACDURO^® and XERAVA^®. Since the formation of IST, now in its second year of operation, we have shown consistent sales expansion in our commercial products, primarily driven by increasing product demand, validating our investment in hospital-based therapeutics,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “Of special note, XACDURO^® was nominated for the Best Biotechnology Product by The Galien Foundation USA in recognition of its pioneering science and positive impact on patients. We are proud of this recognition which highlights the commitment and innovation we are bringing to this space, where there is significant unmet medical need and an immense demand for new drugs. We also continue to further advance our pipeline and are on track to submit a New Drug Application (“NDA”) for zoliflodacin, potentially first in class, single dose oral drug for the treatment of uncomplicated gonorrhea, to the U.S. FDA in early 2025.”

Mr. Raifeld continued, “Over the past quarter, we also saw meaningful operational progress across our strategic healthcare assets. We remain focused on prudent capital allocation in our quest to maximize shareholder value and see multiple opportunities for continued value creation.”

Financial Highlights

• Royalty revenue: Third quarter 2024 gross royalty revenue from Glaxo Group Limited (“GSK”) was $60.5 million, compared to $57.0 million for the third quarter 2023.
• Net Product Sales: Third quarter 2024 net product sales were $27.8 million, which included U.S. net product sales of $19.7 million and ex-U.S. product sales of $8.1 million. U.S. net product sales consisted of $13.1 million from GIAPREZA^®, $2.3 million from XERAVA^®, and $4.3 million from XACDURO^®, a 68% increase compared to $11.8 million for the third quarter 2023.
• License Revenue: Third quarter 2024 license revenue of $4.6 million included product development cost-sharing reimbursements from our partner.
• Equity and long-term investments: Third quarter 2024 unfavorable net change in fair value of equity and long-term investments of $35.2 million was primarily due to lower share price of Armata Pharmaceuticals (“Armata”).
• Net income: Net income of $1.2 million, or $0.02 basic per share, for the third quarter of 2024, compared to a net income of $82.0 million, or $1.26 basic per share, for the third quarter of 2023.
• Cash and cash equivalents: Totaled $260.6 million. Royalty and product sales receivables totaled $91.1 million as of September 30, 2024.

Key Business and R&D Highlights

• XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, a targeted antibacterial treatment for patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
  • XACDURO^® was recently nominated for the 2024 Prix Galien USA Award for Best Biotechnology Product, which recognizes excellence in scientific innovation that improves the state of human health.
• Zoliflodacin: a potential first-in-class, single dose, oral antibiotic is currently being developed in partnership with The Global Antibiotic Research & Development Partnership ("GARDP") for the treatment of patients with uncomplicated gonorrhea.
  • In September 2024, we presented additional findings on our investigational agent zoliflodacin at the 2024 Sexually Transmitted Infections Prevention Conference in Atlanta. The first oral presentation demonstrated that zoliflodacin had potent in vitro activity against 200 clinical isolates, consistent with previous U.S. surveillance data. The second presentation demonstrated that microbiological cure rates for specific subgroups were comparable to the primary endpoint analysis. Safety in these subgroups was also comparable.
  • In October 2024, we had five presentations at IDWeek 2024, which took place in Los Angeles. One oral presentation on zoliflodacin included a review of the unique public-private partnership that led the clinical development of zoliflodacin. The second presentation highlighted the activity of sulbactam-durlobactam and standard-of-care antibiotics against Acinetobacter baumannii-calcoaceticus complex for hospitalized patients in the U.S. Three posters were presented including two on zoliflodacin: In vitro activity against baseline isolates in U.S. participants from the phase 3 trial and a pharmacometrics analysis supporting dose selection. Surveillance data of eravacycline against clinical pathogens, collected worldwide from multiple infections sites during 2018-2022 was also presented.
  • We continue to advance zoliflodacin following its successful Phase 3 clinical trial results and expect to submit an NDA to the U.S. FDA in early 2025.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR^®/BREO^® ELLIPTA^® and ANORO^® ELLIPTA^®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA^® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA^® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.

ANORO^®, RELVAR^® and BREO^® are trademarks of the GSK group of companies.

Forward Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR^®/BREO^® ELLIPTA^®, ANORO^® ELLIPTA^®, GIAPREZA^®, XERAVA^® and XACDURO^® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

INNOVIVA, INC.
Condensed Consolidated Statements of Income and Comprehensive Income
(in thousands, except per share data)
(unaudited)
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
			2024				2023				2024				2023
Revenue:
Royalty revenue, net (1)		$	57,056			$	53,558			$	179,213			$	172,681
Net product sales			27,822				13,701				68,557				40,942
License revenue			4,630				-				19,135				11,000
Total revenue			89,508				67,259				266,905				224,623
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments)			9,990				10,182				29,433				27,910
Cost of license revenue			-				-				-				1,600
Selling, general and administrative			26,219				28,636				84,364				71,913
Research and development			3,551				3,989				9,989				31,566
Amortization of acquired intangible assets			6,511				6,511				19,391				15,274
Changes in fair values of equity method investments, net			18,231				(71,980	)			42,997				(67,886	)
Changes in fair values of equity and long-term investments, net			16,936				2,640				60,827				4,887
Interest and dividend income			(5,500	)			(4,114	)			(13,373	)			(11,032	)
Interest expense			5,807				4,396				17,460				13,205
Other expense, net			914				1,047				3,123				4,289
Total expenses, net			82,659				(18,693	)			254,211				91,726
Income before income taxes			6,849				85,952				12,694				132,897
Income tax expense, net			5,636				3,906				9,634				14,706
Net income and comprehensive income		$	1,213			$	82,046			$	3,060			$	118,191
Net income per share
Basic		$	0.02			$	1.26			$	0.05			$	1.79
Diluted		$	0.02			$	0.98			$	0.05			$	1.45
Shares used to compute net income per share
Basic			62,569				64,953				62,759				66,016
Diluted			62,951				86,164				63,020				87,504

(1) Total net revenue is comprised of the following (in thousands):
		Three Months Ended								Nine Months Ended
		September  30,								September  30,
			2024				2023				2024				2023
		(unaudited)								(unaudited)
Royalties		$	60,512			$	57,014			$	189,581			$	183,049
Amortization of capitalized fees			(3,456	)			(3,456	)			(10,368	)			(10,368	)
Royalty revenue, net		$	57,056			$	53,558			$	179,213			$	172,681

INNOVIVA, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
	September 30,			December 31,
		2024			2023
Assets
Cash and cash equivalents	$	260,630		$	193,513
Royalty and product sale receivables		91,058			84,075
Inventory		34,236			40,737
Prepaid expense and other current assets		14,697			25,894
Property and equipment, net		544			483
Equity and long-term investments		507,718			560,978
Capitalized fees paid, net		73,416			83,784
Right-of-use assets		2,789			2,536
Goodwill		17,905			17,905
Intangible assets		210,944			230,335
Deferred tax asset, net		14,875			-
Other assets		2,800			3,267
Total assets	$	1,231,612		$	1,243,507
Liabilities and stockholders’ equity
Other current liabilities	$	30,357		$	33,435
Accrued interest payable		833			3,422
Deferred revenue		717			1,277
Convertible senior notes, due 2025, net		191,843			191,295
Convertible senior notes, due 2028, net		255,972			254,939
Other long-term liabilities		71,449			71,870
Deferred tax liabilities, net		-			563
Income tax payable, long-term		11,899			11,751
Innoviva stockholders’ equity		668,542			674,955
Total liabilities and stockholders’ equity	$	1,231,612		$	1,243,507

INNOVIVA, INC.
Cash Flows Summary
(in thousands)
(unaudited)
	Nine Months Ended
	September 30,
		2024				2023
Net cash provided by operating activities	$	129,451			$	107,808
Net cash used in investing activities		(48,308	)			(61,610	)
Net cash used in financing activities		(14,026	)			(157,250	)
Net change		67,117				(111,052	)
Cash and cash equivalents at beginning of period		193,513				291,049
Cash and cash equivalents at end of period	$	260,630			$	179,997

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106330461/en/

Innoviva, Inc.

David Patti

Corporate Communications

(908) 421-5971

david.patti@inva.com

Investors and Media:

Argot Partners

(212) 600-1902

innoviva@argotpartners.com

Source: Innoviva, Inc.

FAQ

What was Innoviva's royalty revenue for Q3 2024?

Innoviva's royalty revenue for Q3 2024 was $60.5 million, a 6% increase year-over-year.

How much were Innoviva's net product sales in Q3 2024?

Innoviva's net product sales in Q3 2024 were $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% year-over-year growth.

What was Innoviva's net income for Q3 2024?

Innoviva's net income for Q3 2024 was $1.2 million, or $0.02 per share.

What are Innoviva's cash and cash equivalents as of Q3 2024?

As of Q3 2024, Innoviva had $260.6 million in cash and cash equivalents.

What future plans does Innoviva have for zoliflodacin?

Innoviva plans to submit a New Drug Application for zoliflodacin to the U.S. FDA in early 2025.